CAS · 41575-94-4
Product Overview
Carboplatin is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Grade: | USP Grade |
|---|---|
| Appearance: | White crystalline powder |
| Assay (Calculated on the dried basis): | 98.0% ~ 102.0% |
| Platinum content (Calculated on the dried basis): | 52.0% ~ 53.0% |
| Identification: | Spectrum sample should be consistent with spectrum of reference standard. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay. |
| pH: | 5.0 ~ 7.0 |
| Loss on drying: | 0.5% max |
| Transmittance: | 97% min |
| Water-insoluble matter: | 0.5% max |
| 1.1-Cyclobutanedicarboxylic acid: | 0.5% max |
| Related substances: | Cisplatin: 0.25% max Any individual unspecified impurity: 0.25% max Total impurities: 0.5% max |
| Residual solvent: | Ethanol: 500 ppm max |
| Bacterial endotoxins: | 0.54 EU/mg max |
| Crystalfinity: | Meets the requirements |
Applications
1. Cancer Chemotherapy
Carboplatin is used as a first-line or adjuvant therapy in treating a variety of cancers, including:
Ovarian cancer
Lung cancer (especially non-small cell lung cancer)
Head and neck cancers
Testicular cancer
Bladder cancer
2. Combination Therapy
Frequently administered in combination with other chemotherapeutic agents such as paclitaxel or gemcitabine to enhance treatment efficacy.
Used in neoadjuvant and adjuvant settings to shrink tumors before surgery or eliminate residual disease post-surgery.
3. Research and Development
Carboplatin丨CAS 41575-94-4 serves as a model drug in research on:
Platinum drug resistance mechanisms
DNA damage and repair pathways
Development of novel platinum-based analogs with improved efficacy and reduced toxicity.
Benefits
Reduced toxicity compared to cisplatin, especially less nephrotoxicity, neurotoxicity, and gastrointestinal side effects.
Improved patient tolerance, allowing for higher dosing or combination regimens.
Effective across a broad range of tumor types.
Water-soluble and relatively stable, facilitating intravenous administration.
Conclusion
A concise summary and suitability assessment for this product is available on request. Contact our team to discuss whether it fits your process and quality requirements.